IL1B rs1143623: What Your Genotype Means
The rs1143623 single-nucleotide polymorphism is a common regulatory variant situated in the promoter region of the IL1B gene, historically designated in the literature as -1473G/C. Research links this variant to potential differences in interleukin-1 beta transcriptional activity, postprandial cytokine dynamics, and susceptibility to chronic inflammatory states. However, clinical evidence remains limited and observational, meaning it does not directly diagnose any health condition.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| GG | You carry two copies of the ancestral or major G allele in the IL1B promoter. In experimental cohorts, this baseline genotype has been associated with standard postprandial cytokine and triglyceride levels relative to minor allele carriers. It reflects the most common genetic status across many world populations. | Informational |
| GC | You carry one copy of the G allele and one copy of the minor C allele (frequently designated as -1473G/C in scientific literature). Some observational studies suggest heterozygous individuals may display modest increases in post-meal inflammatory markers like IL-6, though clinical evidence remains limited and inconsistent across cohorts. It is considered an ordinary population variation. | Informational |
| CC | You carry two copies of the minor C allele. Research studies have observed that homozygous carriers can exhibit altered postprandial lipid handling and higher baseline inflammatory reactivity under certain metabolic stressors, although overall clinical risk associations remain mixed and unreplicated in broad populations. It warrants attention as an area of ongoing immunometabolic research rather than a clinical diagnosis. | Higher attention |
Genomic Location and the IL1B Gene
The single-nucleotide polymorphism rs1143623 resides within the non-coding promoter region of the interleukin-1 beta (IL1B) gene on chromosome 2q14.1. In biomedical literature, it is frequently annotated relative to the transcription initiation site as the -1473G/C polymorphism. The IL1B gene codes for interleukin-1 beta, a potent pro-inflammatory cytokine produced largely by activated monocytes, macrophages, and dendritic cells. Interleukin-1 beta plays an indispensable role in orchestrating systemic host defense, initiating fever, recruiting immune cells to sites of infection or tissue damage, and inducing secondary inflammatory mediators like interleukin-6 (IL-6). Because promoter elements regulate the rate at which transcription factors assemble to transcribe mRNA, base changes within these segments can theoretically tune the sensitivity or magnitude of cytokine synthesis. However, rs1143623 is located outside of protein-coding exons, meaning it does not alter the primary amino acid structure or biochemical function of the translated cytokine protein itself.
Research Associations and Biological Mechanisms
Investigational studies have evaluated rs1143623 as a candidate modifier of inflammatory responses, lipid metabolism, and chronic disease susceptibility. In metabolic research, carriers of the minor C allele have demonstrated elevated postprandial lipemia and an amplified release of interleukin-6 following high-fat meals compared to individuals homozygous for the major G allele. Because interleukin-1 beta signaling cascades naturally promote downstream IL-6 production, researchers hypothesize that this promoter variant could modulate acute-phase inflammatory reactivity. Additionally, epidemiological teams have evaluated rs1143623 across various malignancies, such as colorectal and gastric cancers, though meta-analytic evaluations show conflicting outcomes without consistent overall risk across broad populations. Furthermore, laboratory evidence indicates that rs1143623 frequently functions as part of extended multi-SNP haplotypes in the IL1B promoter alongside variants like -511 and -3737, making it difficult to isolate the independent phenotypic contribution of this single position.
Strength of Clinical Evidence
The current clinical validity and scientific strength for rs1143623 are categorized as limited. While molecular biology confirms that interleukin-1 beta is a central driver of human inflammatory pathology, associations specifically attributing altered disease risk to rs1143623 stem primarily from modest candidate-gene case-control cohorts. Broad genome-wide association studies (GWAS) have not established robust, genome-wide significant disease thresholds for this single locus across diverse phenotypes. Many published findings present mixed results; for example, associations observed in specific ethnic cohorts or small clinical subgroups often fail to replicate when combined into larger meta-analyses. Consequently, neither the American College of Medical Genetics and Genomics (ACMG) nor major clinical guideline consortia consider rs1143623 a pathogenic or actionable mutation. The variant should be understood as a modest statistical biomarker within research literature rather than an independent diagnostic determinant.
Understanding Your Results and Practical Applications
Discovering your rs1143623 genotype through commercial or research genotyping reveals an informational glimpse into your inherited immunogenetic architecture, not a clinical diagnosis. Carrying one or two copies of the minor allele does not mean you have or will develop a chronic inflammatory disease, nor does it guarantee altered cytokine levels in your daily life. Complex phenotypes like cardiovascular health, metabolic efficiency, and immune surveillance arise from the interplay of thousands of genetic variants alongside profound environmental variables, including diet, physical activity, sleep hygiene, and toxic exposures. You should not start, stop, or adjust any medication, anti-inflammatory treatment, or dietary supplement based on this result. If you have concerns regarding chronic inflammation, cardiovascular wellness, or inflammatory disorders, discuss comprehensive clinical biomarkers and evidence-based lifestyle modifications directly with a qualified healthcare provider.
How common is this variant?
The rs1143623 variant is common globally, with the minor C allele exhibiting a minor allele frequency (MAF) ranging roughly between 0.30 and 0.45 across diverse continental ancestries.
Frequently asked questions
Does carrying the rs1143623 C allele mean I have chronic inflammation?
No. Carrying the C allele is an observational genetic finding, not a clinical diagnosis. Many individuals carrying one or two copies of this variant maintain normal inflammatory markers throughout life, as lifestyle, diet, and overall genetic background heavily influence immune function.
Can I use rs1143623 to guide my use of anti-inflammatory medications?
No. There are currently no pharmacogenomic guidelines from bodies such as CPIC or PharmGKB that recommend adjusting medications, such as NSAIDs or biologic therapies, based on rs1143623. Always consult your doctor or pharmacist before making any changes to your medication regimen.
Why do scientific studies sometimes refer to rs1143623 as -1473G/C?
Historically, geneticists named variants according to their physical distance upstream of a gene's transcriptional start site. The -1473G/C label refers to its promoter position 1,473 base pairs before the start of the IL1B gene, whereas rs1143623 is the standardized dbSNP reference identifier.
What is the best way to monitor my actual inflammation levels?
Rather than relying on DNA variants, clinical inflammation is typically evaluated through standardized blood tests ordered by a physician, such as high-sensitivity C-reactive protein (hs-CRP) or erythrocyte sedimentation rate (ESR), interpreted alongside a physical examination.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1143623?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29